Stock Alert: Atossa Up 28% On Positive Results From Its COVID-19 Drug Candidate

Shares of Atossa Therapeutics, Inc. (ATOS) are spiking more than 28% Wednesday morning after the clinical-stage biotechnology company announced positive results from the in vitro testing of AT-H201, Atossa's COVID-19 drug candidate.

Preliminary data showed that AT-H201 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture. Vero cells are a lineage of cells used in cell cultures.

"These results support the continued development of AT-H201 for COVID-19 patients and beginning studies in the clinical setting," said Dr. Steven Quay, Atossa's President, and Chief Executive Officer.

Atossa stock is currently trading at $2.25. It has traded in the range of $0.76- $3.25 in the past 52-weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Editors Pick
Teva Pharmaceuticals USA, Inc. has recalled one lot of platelet-reducing drug Anagrelide in the form of capsules due to dissolution test failure detected during routine stability testing, the U.S. Food and Drug Administration, or FDA, said in a statement. The U.S. Food and Drug Administration said it has taken steps to make available millions of cans of additional infant and specialty formula to U.S. consumers in the coming months. Under the agency's recent increased flexibilities, British nutrition products maker Kendal Nutricare will send about 2 million cans of infant formula under the Kendamil brand initially to U.S. beginning in June. Video streaming giant Netflix Inc. announced the availability of a variety of mobile games. Players can download the games directly from the Netflix mobile app. The new games include Dragon Up (East Side Games), Moonlighter (11 Bit Studios), Townsmen - A Kingdom Rebuilt (HandyGames), and Exploding Kittens - The Game (Exploding Kittens Digital).
Follow RTT